Simufilam - Cassava Sciences
Alternative Names: C0105; C0105M; Filora; PTI-125; PTI-910; Simufilam hydrochloride; Sumifilam - Cassava SciencesLatest Information Update: 27 Aug 2024
At a glance
- Originator Pain Therapeutics
- Developer Cassava Sciences
- Class Antidementias; Small molecules
- Mechanism of Action Microfilament protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Alzheimer's disease
Most Recent Events
- 26 Jul 2024 Cassava Sciences initiates a phase I pharmacokinetic trial in USA (PO) (NCT06390410)
- 24 Jul 2024 Chemical structure information added
- 02 May 2024 Cassava Sciences plans a phase I pharmacokinetic trial in July 2024 (NCT06390410)